Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BLU-5937 in Healthy Japanese and Caucasian Adults
NCT06179537Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of camlipixant in chronic cough (3 cohorts), sponsored by GSK. Primary endpoints: Change in ECG QTcF interval, Change in diastolic and systolic blood pressure and 6 more. Started Aug 2021; status: completed.
02
Drugs
camlipixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT06179537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179537.